Detalhe da pesquisa
1.
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Ann Oncol
; 33(4): 384-394, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35093516
2.
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Ann Oncol
; 33(8): 814-823, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35513244
3.
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Ann Oncol
; 32(5): 642-651, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617937
4.
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Ann Oncol
; 30(2): 236-242, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30590484
5.
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.
Ann Oncol
; 26(1): 75-80, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25361988
6.
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Ann Oncol
; 26(7): 1280-91, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26019189
7.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Ann Oncol
; 26(2): 259-71, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25214542
8.
Which threshold for ER positivity? a retrospective study based on 9639 patients.
Ann Oncol
; 25(5): 1004-11, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24562447
9.
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
Ann Oncol
; 25(2): 358-65, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24299959
10.
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer.
Ann Oncol
; 25(6): 1122-7, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24669015
11.
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
Ann Oncol
; 24(3): 647-54, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23337633
12.
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes.
Br J Cancer
; 106(6): 1107-16, 2012 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-22343619
13.
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
Ann Oncol
; 20(12): 1953-8, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19596702
14.
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy.
Ann Oncol
; 19(8): 1402-1406, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18436523
15.
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Ann Oncol
; 19(12): 2020-5, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18667396
16.
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.
Br J Surg
; 95(4): 433-7, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18161887
17.
Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction.
Plast Reconstr Surg
; 139(3): 586e-596e, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28234813
18.
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Cancer Res
; 58(6): 1253-9, 1998 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-9515813
19.
Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis.
Oncogene
; 13(5): 1053-63, 1996 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-8806695
20.
NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity.
Oncogene
; 17(13): 1705-16, 1998 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-9796699